We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Biotech Acquisition Company Class A Ordinary Shares in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 68 → 0 (-68)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $226M → $0 (-$226M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 68

Holders
–
Holders Change
-68
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
68
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
-$23.1M
2
AC
Aristeia Capital
Connecticut
-$15.4M
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$12.7M
4
Marshall Wace
Marshall Wace
United Kingdom
-$10.2M
5
SCM
Saba Capital Management
New York
-$9.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCL
1
Glazer Capital LLC
New York
– -$23.1M -2,283,910 Closed
AC
2
Aristeia Capital
Connecticut
– -$15.4M -1,524,010 Closed
Hudson Bay Capital Management
3
Hudson Bay Capital Management
Connecticut
– -$12.7M -1,261,609 Closed
Marshall Wace
4
Marshall Wace
United Kingdom
– -$10.2M -1,012,642 Closed
SCM
5
Saba Capital Management
New York
– -$9.75M -965,348 Closed
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
– -$9.38M -929,085 Closed
CCP
7
Corbin Capital Partners
New York
– -$9.37M -928,124 Closed
RA
8
RiverPark Advisors
New York
– -$8.07M -799,001 Closed
Millennium Management
9
Millennium Management
New York
– -$7.14M -706,893 Closed
HSBC Holdings
10
HSBC Holdings
United Kingdom
– -$6.45M -638,841 Closed
FTCM
11
Fir Tree Capital Management
New York
– -$6.42M -635,837 Closed
PAMP
12
Polar Asset Management Partners
Ontario, Canada
– -$6.23M -616,700 Closed
MI
13
MMCAP International
Cayman Islands
– -$6.05M -599,321 Closed
AWG
14
Alpha Wave Global
New York
– -$5.38M -532,570 Closed
WCMNY
15
Westchester Capital Management (New York)
New York
– -$5.26M -520,364 Closed
WRBC
16
W.R. Berkley Corp
Connecticut
– -$4.92M -487,311 Closed
RCM
17
Radcliffe Capital Management
Pennsylvania
– -$4.61M -456,764 Closed
DKCM
18
Davidson Kempner Capital Management
New York
– -$4.54M -450,000 Closed
Nomura Holdings
19
Nomura Holdings
Japan
– -$4.04M -400,000 Closed
MF
20
Magnetar Financial
Illinois
– -$3.84M -379,994 Closed
State of Wisconsin Investment Board
21
State of Wisconsin Investment Board
Wisconsin
– -$3.64M -360,000 Closed
RL
22
RPO LLC
Connecticut
– -$3.63M -359,009 Closed
AA
23
AQR Arbitrage
Connecticut
– -$3.55M -351,148 Closed
SC
24
Sculptor Capital
New York
– -$3.04M -300,538 Closed
ACA
25
Arena Capital Advisors
California
– -$3.03M -300,000 Closed
1
2 3

BIOT Hedge Fund Activity: Q1 2023 in Review

0 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q1 2023, worth a combined $0 — down 100% from $226M a quarter earlier.

Sellers outnumbered buyers: 68 funds closed out of BIOT and 0 opened new positions — a net loss of 68 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Glazer Capital LLC, exiting entirely with an estimated $23.1M sold.

  • 0 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q1 2023, down from 68 in Q4 2022.
  • Funds reported $0 of Biotech Acquisition Company Class A Ordinary Shares stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q1 2023 and 68 closed out, a net change of -68 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q1 2023 was Glazer Capital LLC, an estimated $23.1M sold.

Based on aggregated 13F filings for Q1 2023.